Skip to main content
. Author manuscript; available in PMC: 2017 Jun 28.
Published in final edited form as: Sci Signal. 2016 Dec 13;9(458):ra121. doi: 10.1126/scisignal.aaf9109

Fig. 6. Activation of A2bAR attenuates mTOR pathway activation.

Fig. 6

(A) A2b agonist BAY 60-6583 (BAY) attenuates AKT and p70S6K activity. Western blot analysis of AKT phosphorylated on Thr308 (P-AKT T308) or Ser473 (P-AKT S473) and phosphorylated p70S6K (P-p70S6K) relative to total AKT and total p70S6K, respectively. Vehicle or BAY was added at day 9 to control and ACDC iMSCs under osteogenic conditions for 15, 30, or 60 min. Representative images are shown. Densitometry data (right) are means ± SEM, one-way ANOVA with Dunnett’s comparison to time 0, n = 3 independent experiments. *P < 0.05, **P < 0.001. (B) MicroCT analysis in ACDC teratomas with rapamycin (Rapa) treatment or DMSO (Veh) control. Calcification percentage was valued in CT Analyzer software. Data are means ± SEM; DMSO, n = 6 teratomas; rapa-mycin, n = 3 teratomas; *P = 0.0354, unpaired two-tailed Student’s t test.